Listen
LUCENTIS (ranibizumab)
Retinopathy of prematurity
Opinions on drugs -
Posted on
Apr 24 2020
Reason for request
New indication
- Key points
Unfavourable opinion for reimbursement in the indication extension for the treatment of retinopathy of prematurity (ROP).
Clinical Benefit
| Insufficient |
The clinical benefit of LUCENTIS 10 mg/ml solution for injection is insufficient in the indication extension for the treatment of retinopathy of prematurity to justify its funding by the French national health insurance system.
|
Documents
English version
Contact Us
Évaluation des médicaments
